STAGEZERO LIFE SCIENCES LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.04 CAD | 0.00% |
|
0.00% | -11.11% |
| Apr. 11 | North American Morning Briefing : Stock Futures -2- | DJ |
| Apr. 04 | North American Morning Briefing : Focus Turns to -2- | DJ |
| Sales 2021 | 5.07M 6.98M | Sales 2022 | 3.8M 5.23M | Capitalization | 4.49M 6.19M |
|---|---|---|---|---|---|
| Net income 2021 | -7M -9.64M | Net income 2022 | -11M -15.14M | EV / Sales 2021 | 3.99 x |
| Net cash position 2021 | 368K 507K | Net Debt 2022 | 1.78M 2.46M | EV / Sales 2022 | 1.65 x |
| P/E ratio 2021 |
-2.2
x | P/E ratio 2022 |
-0.39
x | Employees | 40 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 79.63% |
More Fundamentals
* Assessed data
More news
Latest transcript on StageZero Life Sciences Ltd.
More press releases
| Current month | -20.00% | ||
| 1 month | -11.11% | ||
| 3 months | -11.11% | ||
| 6 months | -20.00% | ||
| Current year | -11.11% |
1 month
0.04
0.06
Current year
0.040.06
1 year
0.040.09
3 years
0.040.79
5 years
0.041.65
10 years
0.0015.52
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | - | 01-12-31 | |
Rebecca Greco
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Rory Riggs
FOU | Founder | 71 | 97-12-31 |
Garth MacRae
BRD | Director/Board Member | 90 | 99-12-31 |
| Chief Executive Officer | - | 01-12-31 |
StageZero Life Sciences, Ltd. is a Canada-based vertically integrated healthcare company. The Company is focused on improving the early detection and management of cancer and other chronic diseases through diagnostics telehealth programs. Its lead product, Aristotle, is a mRNA multi-cancer panel for simultaneously screening for multiple cancers from a single sample of blood with high sensitivity and specificity for each cancer. The Care Oncology Clinic offers a supervised treatment regimen for people diagnosed with cancer of any type or stage. AVRT is a physician-led, telehealth program for identifying and managing the early warning signs of cancer and chronic disease. Its program includes a comprehensive online health evaluation; bloodtests to measure markers of inflammation and metabolism; an initial physician consultation; regular physician follow-up appointments and interval screening. Its additional cancer diagnostics include ColonSentry and the Prostate Health Index.
Calendar
2024-05-14
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -11.11% | 3.58M | |
| -1.78% | 41.71B | |
| +47.70% | 41.56B | |
| +4.01% | 39.74B | |
| -15.14% | 25.61B | |
| +3.16% | 24.26B | |
| -24.08% | 18.55B | |
| -2.67% | 11.93B | |
| +24.76% | 11.93B | |
| +7.01% | 10.91B |
- Stock Market
- Equities
- SZLS Stock
